<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144477">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732185</url>
  </required_header>
  <id_info>
    <org_study_id>P100510</org_study_id>
    <nct_id>NCT01732185</nct_id>
  </id_info>
  <brief_title>Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations</brief_title>
  <acronym>MAKP</acronym>
  <official_title>Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify genetic abnormalities and molecular pathways associated
      with the occurrence of CCAM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congenital lung malformations are rare diseases, characterized by the coexistence in the
      same individual of normal lung and localized lung malformation. Among these malformations,
      congenital cystic adenomatoid malformations (CCAM) represent the most important group, with
      an estimated incidence between 1/11 000 and 1/35 000 births. The precise mechanisms leading
      to these lung malformations remain poorly understood. This project aims to identify key
      genetic and/or molecular mechanisms associated with the occurrence of CCAM. CCAMs are
      collected during postnatal surgical resection. Parental agreement is required. A
      standardised histologic description of malformations is performed for each sample. Normal
      lung tissue at the periphery of the malformation is considered as control. Malformations
      will be analyzed in a systematic way by proteome and transcriptome, after laser
      microdissection. Somatic genetic abnormalities will also systematically be sought.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>mRNA expression</measure>
    <time_frame>at Day 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Transcriptomic analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein expression</measure>
    <time_frame>at Day 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proteomic expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatic genetic abnormalities</measure>
    <time_frame>at Day 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>CGH array</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Congenital Cystic Adenomatoid Malformation (CCAM)</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>congenital cystic adenomatoid malformations</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Patient</intervention_name>
    <description>Blood and histological samples will be done at day of the inclusion.</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children &lt; 8 years

          -  Thoracic surgery for congenital lung malformation

          -  Parental written consent

        Exclusion Criteria:

          -  Children &gt; 8 years

          -  Previous infection of the malformation

          -  Parental rebutal
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Delacourt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necker-Enfants Malades Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Delacourt, MD, PhD</last_name>
    <phone>+ 33 1 44 49 49 55</phone>
    <email>christophe.delacourt@nck.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Lecomte, PhD</last_name>
    <phone>+33 1 71 19 64 94</phone>
    <email>laurence.lecomte@nck.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Necker-Enfants Malades Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Delacourt, MD, PhD</last_name>
      <phone>+ 33 1 44 49 49 55</phone>
      <email>christophe.delacourt@nck.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Kotecha S, Barbato A, Bush A, Claus F, Davenport M, Delacourt C, Deprest J, Eber E, Frenckner B, Greenough A, Nicholson AG, Antón-Pacheco JL, Midulla F. Antenatal and postnatal management of congenital cystic adenomatoid malformation. Paediatr Respir Rev. 2012 Sep;13(3):162-70; quiz 170-1. doi: 10.1016/j.prrv.2012.01.002. Epub 2012 Apr 25. Review.</citation>
    <PMID>22726873</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>August 2, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital lung malformation</keyword>
  <keyword>Congenital Cystic Adenomatoid Malformation</keyword>
  <keyword>Cystic lung disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Cystic Adenomatoid Malformation of Lung, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
